OrganOx develops and commercializes organ perfusion technology to keep donor organs viable for transplantation. The flagship metra device perfuses livers with oxygenated blood at body temperature, delivering nutrients and drugs to mimic normal physiology and allow viability assessment for up to 24 hours. Unlike traditional cold storage, it maintains normothermic conditions and offers direct organ assessment and longer preservation; it leases devices to transplant centers and uses disposable sets. Its goal is to increase transplantable livers and expand to other organs and applications.
Company Size
201-500
Company Stage
Acquired
Total Funding
$73.9M
Headquarters
Oxford, United Kingdom
Founded
2008
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?